德曲妥珠单抗治疗获得性HER2高水平扩增的EGFR突变肺腺癌:病例报道OA
Trastuzumab Deruxtecan for EGFR-mutant Lung Adenocarcinoma with Acquired High-level HER2 Amplification:A Case Report
德曲妥珠单抗是新近研发的抗体偶联药物(antibody-drug conjugate,ADC),用于克服人生长因子受体2(human epidermal growth factor receptor 2,HER2)异常改变.研究已证实其用于既往接受过治疗的HER2突变型非小细胞肺癌(non-small cell lung cancer,NSCLC)患者,疗效可观且安全性可控.然而,该药用于治疗获得性HER2扩增的NSCLC的疗效数据较为有限.本文报道1例转移性肺腺癌患者,在二线奥希替尼治疗后出现获得性HER2的高水平扩增(扩增倍数达20拷贝),经减量德曲妥珠单抗治疗后达到部分缓解(partial response,PR).血浆二代测序(next-generation sequencing,NGS)结果进一步证实HER2扩增被成功抑制.
Trastuzumab deruxtecan is a newly developed antibody-drug conjugate(ADC)designed to overcome human epidermal growth factor receptor 2(HER2)aberrations.Studies have confirmed that Trastuzumab deruxtecan yields promising efficacy with a manageable safety profile in previously treated non-small cell lung cancer(NSCLC)patients harbor-ing HER2 mutations.However,data on efficacy of Trastuzumab deruxtecan for acquired HER2-amplified NSCLC are limited.Here,we report a case of a patient with metastatic lung adenocarcinoma who developed acquired high-level HER2 amplifica-tion(20 copies)after 2nd-line Osimertinib.A partial response(PR)was achieved with reduced-dose Trastuzumab deruxtecan.Plasma next-generation sequencing(NGS)further confirmed successful inhibition of HER2 amplification.
葛晓晓;陈鹤峰;崔少华
200040 上海,复旦大学附属华东医院呼吸与危重症医学科200040 上海,复旦大学附属华东医院呼吸与危重症医学科200040 上海,复旦大学附属华东医院呼吸与危重症医学科
肺肿瘤德曲妥珠单抗HER2扩增获得性耐药病例报道
Lung neoplasmsTrastuzumab deruxtecanHER2 amplificationAcquired resistanceCase report
《中国肺癌杂志》 2026 (3)
229-232,4
This paper was supported by the grants from the Key Discipline Project of Huadong Hospital,Fudan University(No.ZDXK2216,to the Department of Pulmonary and Critical Care Medicine,Huadong Hospital,Fudan University)and the Key Project of Huadong Hospital,Fudan University(No.2019jc028,to Xiaoxiao GE). 本文受复旦大学附属华东医院重点学科(No.ZDXK2216)和复旦大学附属华东医院重点项目(No.2019jc028)资助
评论